• Expanded retail partnerships with Rural King to increase product availability in 2025
• Widened U.S. operations by relocating MVR golf cart production to avoid tariffs and improve quality control
• Grew distribution network with a new Illinois center, reducing fulfillment times
• Added assembly robotics, increasing efficiency, while launching new products in best-selling UTV line

Massimo (NASDAQ: MAMO) has been actively enhancing its market presence and operational efficiency through strategic partnerships and logistical expansions. These initiatives aim to strengthen the company’s position in the powersports and recreational vehicle industry.

Strategic Partnerships Enhancing Market Reach

A significant development is Massimo’s expanded partnership with Rural King, a prominent farm and home retailer with over 130 locations in the U.S. Building upon a successful year of offering go-karts, the collaboration will broaden in 2025 to include a wider range of products such as UTVs, ATVs, go-karts, golf carts, and mini bikes. These products will be available both online and in select Rural King stores, increasing Massimo’s accessibility to a diverse customer base.

Expansion of Distribution and Production Facilities

To meet growing demand and improve service efficiency, Massimo has inaugurated its sixth U.S. distribution center, located in Edwardsville, Illinois. This facility is designed to serve as a key hub in the Midwest, enhancing the company’s logistics network by reducing fulfillment times and optimizing operational costs.

In a strategic move to mitigate tariff risks and enhance quality control during a time of transformation, Massimo has relocated its MVR golf cart production to its facility in Garland, Texas. This decision underscores the company’s commitment to maintaining high manufacturing standards and responsiveness to market dynamics.

Product Innovation and Market Expansion

Looking ahead, Massimo plans to introduce new vehicles to the market. For instance, the company recently rolled out its all-new Buck 550-6 Crew, a six-person UTV starting at a very reasonable $11,999, complete with GPS navigation, lights, and half doors. The workhorse is now available at Massimo’s more than 2,800 partner locations.

In December, the company ramped up its assembly line in Garland, boosting efficiency by 50% with the implementation of some assembly robotics. The optimization dovetailed with the launch of the new T-Boss 560L and 760L UTV models with winter-ready features.

The T-Boss Winter Series line now features a fully enclosed cab with heaters, providing comfort and functionality during harsh winter conditions. These updates were introduced in direct response to customer feedback and underscore Massimo’s dedication to innovation and meeting market demand.

Despite a tough third quarter in 2024, Massimo delivered strong revenue and gross profit over the first nine months of the year. We believe 2025 is looking promising. Massimo’s strategic partnerships, expanded distribution network, and commitment to innovation reflect a proactive approach to growth and competitiveness in the powersports and recreational vehicle market. We expect these initiatives will position the company to effectively meet evolving consumer demands and navigate industry challenges.

For more information, visit the company’s website at massimomotor.com, massimomarine.com, and massimoelectric.com

NOTE TO INVESTORS: The latest news and updates relating to MAMO are available in the company’s newsroom at https://ibn.fm/MAMO

• Recent Zacks report supports a $35 per share valuation and provides an in-depth evaluation of Soligenix.
• The Zacks report underscores Soligenix’s strategic focus on rare diseases and areas lacking effective treatments.
• Financially, Soligenix has demonstrated resilience amid the challenges inherent in biopharmaceutical development.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases, has recently been the focus of a comprehensive analysis by Zacks Small-Cap Research (https://ibn.fm/OpnDo). The report supports a $35 per share valuation and provides an in-depth evaluation of Soligenix’s diverse product pipeline, financial health and strategic positioning within the biopharmaceutical industry.

“Soligenix’s ThermoVax(R) platform continues to produce encouraging results, in this case with a vaccine targeting SARS-CoV-2,” the report stated. “The ability to use CiVax(TM) as a booster following a primary immunization with a different vaccine technology showcases a tremendous advantage for the platform. Looking ahead to 2025, we anticipate updates regarding the phase 3 FLASH2 trial, which we are very confident will be successful based on the results of the FLASH trial, along with results from the phase 2 trials of SGX302 in mild-to-moderate psoriasis and SGX945 in Behcet’s disease. With no changes to our model, our valuation remains at $35 per share.”

The Zacks report underscores Soligenix’s strategic focus on rare diseases and areas lacking effective treatments, highlighting the potential for market exclusivity and premium pricing. This approach positions the company to address critical gaps in patient care while potentially achieving favorable financial outcomes.

Zacks noted that Soligenix “recently announced a publication in the journal ‘COVID’ highlighting preclinical results showing that CiVax(TM), a thermostabilized subunit vaccine against SARS-CoV-2, in combination with a primary adenovirus vaccine induced broader protection against COVID-19 variants in nonhuman primates than a two-shot mRNA series. The company’s ThermoVax(R) platform has previously produced efficacious, thermostabilized vaccines for ricin toxin and filoviruses (Ebola, Marburg, etc.).”

Financially, Soligenix has demonstrated resilience amid the challenges inherent in biopharmaceutical development. Earlier this year, Soligenix announced that it has fully repaid and terminated its loan and security agreement with Pontifax Medison Finance, effectively releasing the company from all related obligations and liens (https://ibn.fm/tgrIl), reflecting prudent financial management and a strong equity position.

In the context of the broader industry, Soligenix’s focus on developing treatments for rare diseases aligns with current trends emphasizing personalized medicine and targeted therapies. The company’s innovative approaches, particularly in areas such as photodynamic therapy for cutaneous T-cell lymphoma (“CTCL”), a rare and chronic cancer, position it to potentially capture significant market share upon successful commercialization.

The Zacks report also highlights the inherent risks associated with biopharmaceutical development, including regulatory hurdles, clinical trial outcomes and market acceptance. However, it notes that Soligenix’s diversified pipeline and strategic focus on unmet medical needs may mitigate some of these risks, offering multiple avenues for potential success.

Investors and stakeholders are encouraged to consider the comprehensive analysis provided by Zacks Small-Cap Research to gain a deeper understanding of Soligenix’s current standing and future prospects. As the company advances its clinical programs and moves closer to potential product approvals, its progress will be closely monitored within the biopharmaceutical community.

Headquartered in Princeton, New Jersey, Soligenix operates within the medical, biomedical and genetics sector. The company’s portfolio encompasses both specialized biotherapeutics and public health solutions, targeting areas with significant unmet medical needs. Among its leading candidates are HyBryte(TM) (SGX301), a photodynamic therapy for CTCL, and SGX942 (dusquetide), designed to address oral mucositis in patients undergoing chemoradiation for head and neck cancer.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• A shaft tailored to a golfer’s unique swing can enhance performance by optimizing swing speed, ball trajectory and overall control.
• Newton Golf Company offers high-quality, custom-fitted shafts that are redefining how golfers approach their game.
• NWTG is not only enhancing golf equipment but also empowering players of all levels to unlock their true potential on the course.

Golf is a sport that demands precision, consistency and control, where even the smallest adjustments in equipment can significantly impact performance. One of the most critical yet often overlooked components of a golf club is the shaft, frequently referred to as the “engine” of the club. Newton Golf Company (NASDAQ: NWTG), a technology-forward golf-equipment manufacturer, understands the importance of this key piece of equipment and is dedicated to becoming a leader in the shaft space.

While many golfers place considerable emphasis on selecting the right clubhead or grip, the importance of using a properly fitted shaft cannot be overstated. A shaft tailored to a golfer’s unique swing can enhance performance by optimizing swing speed, ball trajectory and overall control.

A study published in the Journal of Sports Engineering and Technology indicates that custom club fitting can enhance golf swing characteristics, though the improvements may vary based on the golfer’s skill level (https://ibn.fm/GCLwY). Additionally, a 2023 report by Golf Datatech indicates that golfers are increasingly satisfied with custom fitting experiences, noting positive impacts on their game improvement (https://ibn.fm/dkd4e). These findings suggest that custom-fitted golf shafts can lead to better performance and greater enjoyment on the course.

Fitted shafts are customized to align with a golfer’s specific swing characteristics, including tempo, angle of attack and desired launch conditions. In contrast, standard off-the-shelf shafts may not suit every player, leading to inconsistent results and missed opportunities on the course. A properly fitted shaft minimizes the likelihood of mishits and inconsistency by adapting to a player’s individual swing dynamics. For example, golfers with faster swing speeds may require a stiffer shaft to prevent excessive flex, while those with slower swings often benefit from a more flexible shaft that maximizes launch and distance. Shaft flex, weight and torque all play critical roles in influencing ball flight, and custom fitting ensures these factors are precisely calibrated to meet a player’s needs.

Additionally, fitted shafts enhance shot dispersion, providing greater control and consistency. Golfers using standard shafts often encounter erratic ball flights due to mismatched shaft characteristics. Custom-fitted shafts address these inconsistencies by aligning the club’s performance with the golfer’s natural tendencies, resulting in more predictable ball behavior and improved course management.

Newton Golf Company is emerging as a leader in the golf-equipment space by offering high-quality, custom-fitted shafts that are redefining how golfers approach their game. While Newton Golf caters to players across all skill levels, its innovative technologies are engineered to meet the demands of players on professional tours, with 30 PGA TOUR Champions players trusting the shaft—including Doug Barron, who captured his first major title at the Regions Tradition. Specializing in precision-engineered golf shafts, Newton Golf caters to players across all skill levels. The company’s deep understanding of golf-swing biomechanics and the critical role shafts play in performance has enabled the company to develop a line of premium shafts that deliver measurable results on the course.

Newton Golf distinguishes itself through its commitment to innovation and an unwavering focus on quality. Made in the U.S.A. at Newton Golf’s facility in St. Joseph, Missouri, the company utilizes advanced materials and engineering techniques to produce shafts that meet the highest performance standards. NWTG’s proprietary technology customizes shafts based on detailed swing data, helping golfers optimize distance, control and feel. As a result, players experience better consistency and accuracy while gaining increased confidence in their equipment.

By focusing on an often-underestimated aspect of a golfer’s performance, Newton Golf Company is solidifying its position as a key player in the competitive golf-equipment market. Offering a diverse range of fitted shafts that enhance performance across various skill levels, the company is strengthening its reputation for delivering superior quality and precision. As more players recognize the benefits of using custom-fitted shafts, Newton Golf’s influence in the golf industry continues to grow.

With the golf industry evolving to meet the demands of players seeking more personalized equipment, the importance of using high-quality, fitted shafts is becoming increasingly clear. Newton Golf is leading this transformation, offering golfers the opportunity to optimize their performance with equipment tailored to their unique swing dynamics. As the company continues to expand its product offerings and refine its technology, Newton Golf is not only enhancing golf equipment but also empowering players of all levels to unlock their true potential on the course.

For more information, visit www.NewtonGolfCo.com.

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

On April 22, 2025, the Centri Capital Conference will take place at Nasdaq in New York City, bringing together investors, companies, and industry leaders to explore opportunities in the capital markets. This invite-only event requires registration approval.

Designed to foster meaningful connections, the conference will bridge the gap between growth-focused private and public companies and investors seeking innovative investment opportunities. Attendees will engage with dynamic speakers, expert panelists, and presenting companies from high-growth sectors such as life sciences, healthcare and disruptive technology.

The one-day event will feature dynamic company presentations, one-on-one meetings, and panel discussions. Growth-oriented companies will have the opportunity to showcase their latest innovations, leveraging the conference’s expansive platform to gain visibility among key industry players.

The panel lineup will feature leading experts discussing crucial industry topics, including the IPO Market, Blockchain and Cryptocurrency Dynamics, AI, and Capital Strategies for Innovative Companies, among others.

Key highlights of the conference include:

• Presentations from select companies highlighting their growth potential and investment opportunities
• Curated one-on-one meetings between investors and presenting companies
• Expert-led panel discussions on industry trends, investment strategies, and emerging growth sectors
• Networking opportunities with investors, industry leaders, and sponsors

The Centri Capital Conference provides a unique platform for investors to discover new opportunities and for companies to access capital and strategic partnerships. Companies will have the chance to deliver compelling presentations and engage in meaningful one-on-one discussions to build long-term collaborations.

To register, please visit here.

• D-Wave’s research shows that quantum-based blockchain operations could use up to 1,000 times less electricity than classical computing methods.
• In an industry first, D-Wave successfully deployed blockchain operations across four of its cloud-based quantum computers in North America.
• The company’s proof of quantum work algorithm leverages quantum-generated hashes, providing an added security layer.
• The novel quantum blockchain architecture follows the company’s recent quantum supremacy demonstration, serving as another example of how D-Wave helps customers realize the value of quantum computing now.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, has published a research paper introducing a new quantum blockchain architecture that could improve security and significantly reduce the electricity required for blockchain operations (https://ibn.fm/Tndwv). The paper, “Blockchain with Proof of Quantum Work,” details how quantum computing can be used to generate and validate blockchain transactions more efficiently than classical computers (https://ibn.fm/6nVTE).

The company has also conducted the first-ever demonstration of distributed quantum computing for blockchain. This involved deploying the new blockchain architecture across four of its cloud-based quantum computers located in Canada and the United States. According to D-Wave, the results show that quantum computing can support stable blockchain operations across different generations of hardware. “This is the first time a blockchain has successfully operated on a distributed network of four quantum computers across two countries,” said Dr. Mohammad Amin, chief scientist at D-Wave.

Traditional blockchains rely on hashing functions and proof of work (“PoW”) algorithms to validate transactions. These operations are computationally demanding and consume significant amounts of electricity. For example, Bitcoin mining alone is estimated to use as much electricity annually as Poland consumes.

D-Wave’s paper highlights how the company built and tested a “proof of quantum work” algorithm that uses quantum computation to generate and validate blockchain hashes. The research shows that replacing classical computation with quantum-based hashing and proof of work could lead to significant energy savings. The paper states that, in this context, the proof of quantum work algorithm could reduce electricity consumption by up to a factor of 1,000.

Furthermore, this algorithm could enhance security by generating blockchain hashes using quantum computation, instead of classical computers. By integrating quantum-generated hashes, the system can eliminate some of the vulnerabilities associated with traditional proof-of-work models.

D-Wave’s approach relies on programmable spin glasses, which were used in its recent quantum supremacy demonstration. These quantum-generated hashes provide a more complex security framework than classical methods, potentially making blockchain networks more resistant to attacks.

“Despite spanning two generations of D-Wave annealing quantum computers with different architectures and fabrication stacks, the systems’ outputs were able to cross-validate each other and facilitate stable blockchain operation for thousands of transaction blocks. We believe that this approach could significantly reduce energy consumption and enhance security,” Dr. Amin added.

Blockchain technology has applications beyond cryptocurrency, including supply chain management, healthcare, identity verification, and decentralized finance. The introduction of quantum-powered blockchain could address some of the scalability and energy consumption challenges currently faced by blockchain networks.

D-Wave is inviting businesses and researchers to explore potential use cases for this technology. The D-Wave(TM) annealing quantum computers used in the company’s recent quantum supremacy demonstration and this new blockchain research are available for customers to use today via D-Wave’s Leap(TM) real-time quantum cloud service.

“Coming off the heels of our recent quantum supremacy demonstration, this serves as yet another example of how D-Wave is helping customers realize the value of quantum computing now,” said Dr. Alan Baratz, CEO of D-Wave. “We invite the blockchain community to work with us to utilize this exciting new use case for quantum computing.”

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our 5,000+ qubit Advantage(TM) quantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our Advantage and Advantage2(TM) systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

• The company’s AI-driven software helps clinics transition to value-based care and optimize revenue streams, offering providers superior visibility into insurance contracts and associated reimbursements.
• Adageis provides advocacy for healthcare organizations, identifying discrepancies in payments and ensuring they are fairly compensated for services.
• The platform allows providers to assess which insurance contracts align best with their financial goals and patient care priorities, improving financial planning.

Healthcare providers often struggle to navigate complex insurance contracts to determine whether they are receiving proper reimbursement for services. A lack of transparency in how the process unfolds can result in lost revenue and financial instability, particularly for smaller clinics and new practices.

Adageis, a forward-thinking healthcare technology company, is reshaping patient care through flexible AI-centric software solutions for healthcare organizations. The company offers a software solution designed to help providers understand what they should be paid under each insurance contract, with insights into revenue expectations.

Adageis’ AI-driven platform allows clinics to quickly and easily:

• Compare expected vs. actual payments from insurance companies
• Identify underpayments and reimbursement gaps
• Analyze financial performance under different contracts

By providing real-time visibility into these details, healthcare organizations can make more informed decisions about contract negotiations and patient care models.

As healthcare moves away from fee-for-service models toward value-based care, many providers struggle to adjust. Adageis offers tools to help new practices transition smoothly to value-based care structures, highlighting the most profitable insurance contracts while maintaining high-quality care, and ensuring that providers are fairly compensated for delivering effective patient outcomes.

Beyond financial insights, Adageis positions itself as an advocate for healthcare providers. The company’s technology enables organizations to negotiate better contracts with insurers, providing clarity on expected revenue before signing agreements, and making sure they are paid what they are owed for patient care. By empowering providers with solid data, Adageis aims to level the playing field between healthcare organizations and insurers.

The healthcare technology sector is experiencing growing investor interest, particularly in solutions that address billing inefficiencies and revenue optimization. Adageis offers practical AI applications in healthcare finance, designed to provide increased transparency, simplicity, and real financial gains. The company stands out as a promising investment opportunity in a rapidly evolving landscape.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

• MAMO recently participated in several vendor events to strengthen strategic retail partnerships
• Company recognizes “our success is intrinsically tied to our retail partners and the communities they serve,” states CEO
• By engaging directly with retail partners, Massimo Group gains invaluable insights into customer preferences and emerging trends

In today’s competitive business environment, robust retail partnerships are essential for companies aiming to expand their market reach and enhance brand visibility. Such collaborations enable businesses to leverage the strengths of their partners, ensuring products and services are accessible to a broader customer base. Massimo Group (NASDAQ: MAMO), a manufacturer of powersports vehicles, exemplifies this strategy by actively engaging in key industry events to fortify its retail alliances.

According to the company, Massimo Motor recently participated in the Rural King Vendor Summit, the Tractor Supply Company & PetSense Annual Supplier Meeting (“ASM”), and the Partner Trade Show (ibn.fm/Sm8eG). These events serve as platforms for suppliers and retailers to collaborate, discuss market trends and align strategies to meet consumer demands effectively. Massimo’s involvement underscores its commitment to strengthening relationships with major retail partners, ensuring its products are accessible to a broad consumer base.

“At Massimo Motor, we recognize that our success is intrinsically tied to our retail partners and the communities they serve,” said David Shan, CEO of Massimo Motor. “The customers who shop at Rural King and Tractor Supply demand quality, reliability and affordability, and we are committed to delivering products that exceed those expectations.”

Massimo’s participation in these vendor summits is not only about showcasing its lineup of UTVs, ATVs and other outdoor vehicles, but also about listening and learning. By engaging directly with retail partners, the company gains invaluable insights into customer preferences, emerging market trends and opportunities for improvement. This knowledge enables Massimo to refine its product offerings and ensure its vehicles deliver the durability and performance that rural customers rely on for work and recreation.

The shared customer base between Massimo, Rural King and Tractor Supply “represents a segment of consumers who prioritize practicality, value and high-quality equipment,” the company stated. “By maintaining a close partnership with these retailers, Massimo reinforces its commitment to providing vehicles that meet the real-world needs of farmers, ranchers and outdoor enthusiasts across the country.”

The company also noted that its participation in these types of events represents its proactive approach to market expansion and strategic growth. “Strengthening partnerships with established retail leaders ensures that Massimo products remain competitive, accessible, and positioned for long-term success,” the company observed.

In addition to strengthening retail partnerships, Massimo has made strategic moves to enhance its operational efficiency. The company recently announced the transition of its MVR Golf Cart series production to its facility in Garland, Texas. This move aims to improve quality control and streamline production processes, further solidifying Massimo’s commitment to delivering top-notch products to its customers.

MAMO’s strategic emphasis on strengthening retail partnerships, coupled with its commitment to innovation and quality, positions the company well in the competitive powersports industry. By aligning closely with key retailers and focusing on delivering value-packed products through the launch of its new online sales platform, Massimo is poised to meet the evolving needs of consumers and maintain its growth trajectory in the market.

Founded in 2009, Massimo Motor has established itself as a key player in the powersports industry. The company operates a 376,000-square-foot facility in Garland, Texas, where it designs and manufactures a diverse range of vehicles. Massimo’s product lineup includes utility task vehicles (“UTVs”), all-terrain vehicles (“ATVs”), and other off-road and on-road vehicles, all known for their performance, durability, and affordability. This diverse portfolio caters to both recreational enthusiasts and professionals seeking reliable machinery for various tasks.

For more information, visit the company’s website at massimomotor.com, massimomarine.com, and massimoelectric.com

NOTE TO INVESTORS: The latest news and updates relating to MAMO are available in the company’s newsroom at https://ibn.fm/MAMO

The MoneyShow Income, Growth, & Value Virtual Expo will be held from April 29-30, 2025, as a virtual event. The online conference features the financial industry’s brightest minds sharing their wisdom and advice. Attendees can connect with them during the LIVE presentations and get their queries solved.

The MoneyShow Virtual Expo will show investors how they can both safeguard and grow their portfolios. Attendees can directly chat with distinguished experts to learn pro tips on creating a strong and diverse portfolio. The MoneyShow organization brings in 44 years of industry experience offering traders and investors sound financial and trading advice, resources, and collaboration opportunities to enable them to build their wealth.

Whether you’re a seasoned investor or a newcomer, you won’t want to miss the event.

Top Reasons to Attend:

• Gain valuable insights from top financial experts.
• Learn about income-generating investments, growth opportunities, and value-based strategies.
• Network with like-minded investors and traders.
• Learn about key market trends and make informed investment decisions.

From growth-stage to veteran companies, several players will showcase their products, services, and investment opportunities. Experts will offer live market analysis and sound recommendations on many investment topics. Attendees can connect with industry experts, investors, and peers to explore new investment opportunities and expand their horizons.

Attendees will also have access to interactive, virtual booths that offer message boards, research data, educational videos, phenomenal discounts, and other valuable information. To top it all off, the event provides a digital briefcase for attendees to assemble, download, and store all the collected information in one place.

To learn more, please visit https://ibn.fm/ofEPM.

• Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026.
• SNGX’s HyBryte is a novel photodynamic therapy using synthetic hypericin activated by safe visible light.
• The ongoing phase 3 replication study meets stringent requirements of regulatory agencies to strengthen the case for HyBryte as a commercially available treatment.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases and unmet medical needs, is making significant strides in its efforts to bring innovative therapies to patients with early-stage cutaneous T-cell lymphoma (“CTCL”). The company’s lead candidate, HyBryte(TM) (“SGX301”), has already demonstrated positive results in a prior phase 3 trial, and Soligenix is now conducting a phase 3 replication study to further validate its efficacy and safety (https://ibn.fm/zdRnQ). This development marks an important milestone in the company’s mission to address an urgent medical need in a condition with limited treatment options.

“We are pleased to be initiating patient enrollment into our FLASH2 study,” said Soligenix president and CEO Christopher J. Schaber (https://ibn.fm/LjfXu). “FLASH2 is expected to enroll patients in the United States and Europe, with a formal interim analysis anticipated early in 2026. Given the extensive engagement with the CTCL community, the esteemed Medical Advisory Boards in the U.S. and Europe, key patient advocacy groups like the Cutaneous Lymphoma Foundation, as well as our previous trial experience with this disease, accelerated enrollment in support of this study is anticipated. We look forward to providing periodic updates on the trial’s progress in 2025.”

CTCL is a rare and chronic form of non-Hodgkin’s lymphoma that primarily affects the skin, leading to symptoms such as red, scaly patches, growths and severe itching (https://ibn.fm/JXiDN). Patients with early-stage CTCL often struggle to find effective treatments that are both safe and well-tolerated over long periods. Current treatment options include corticosteroids, phototherapy and chemotherapy. These treatments often come with limitations, such as toxicity, inconsistent responses and adverse side effects.

HyBryte(TM) is a novel photodynamic therapy using synthetic hypericin activated by safe visible light. This revolutionary treatment offers a potentially game-changing approach by providing a noninvasive, well-tolerated alternative that targets malignant T-cells with precision.

The initial phase 3 trial (“FLASH”) of HyBryte(TM) showed strong efficacy, demonstrating a statistically significant response in patients compared to placebo. The study results indicated that HyBryte(TM) was not only effective in reducing lesion size and severity but also presented a favorable safety profile, making it a compelling option for long-term disease management. The positive data from this initial trial has led Soligenix to move forward with the FLASH2 replication study, which aims to confirm the results in a larger patient population and further establish HyBryte(TM) as a viable front-line treatment for early-stage CTCL.

The ongoing phase 3 replication study is designed to potentially meet the stringent requirements of regulatory agencies, in order to strengthen the case for HyBryte(TM) as a commercially available treatment. If successful, this study could pave the way for regulatory approval worldwide, bringing a much-needed new option to patients who have long been underserved by existing therapies. The ability of HyBryte(TM) to deliver effective results with minimal systemic exposure makes it particularly well-suited for chronic conditions such as CTCL, where long-term management is essential.

Soligenix is positioning itself as a leader in the rare disease space by focusing on therapies that address critical gaps in treatment. In addition to HyBryte(TM), the company has a diversified pipeline that includes other promising candidates targeting conditions such as oral mucositis, and Behcet’s Disease, as well as mild-to-moderate psoriasis. By leveraging its proprietary drug development expertise and commitment to scientific rigor, Soligenix is working to bring life-changing treatments to patients who have few, if any, safe and effective therapeutic alternatives.

The significance of Soligenix’s phase 3 replication study extends beyond just the CTCL community. Success in this trial could reinforce the company’s broader strategy of using innovative therapeutic approaches to tackle rare and difficult-to-treat diseases. The progress of HyBryte(TM) also highlights the importance of photodynamic therapy as a novel and effective modality that could potentially be applied to other dermatological and oncological conditions.

As Soligenix moves forward with its pivotal phase 3 replication study, industry observers, investors, and medical professionals will be closely monitoring the results. A positive outcome could not only validate HyBryte(TM) as a groundbreaking treatment for early-stage CTCL but also elevate Soligenix’s standing as a leader in the rare-disease treatment space. The company remains dedicated to advancing its research and bringing new hope to patients facing life-altering conditions with limited treatment options.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• Solving the ongoing hospitality labor crisis can create billion-dollar companies
• Nightfood’s unique RaaS business model lowers barriers to entry while maximizing revenue per client
• Nightfood’s subsidiaries Skytech and Future Hospitality Ventures (RoboOp365) provide breakthrough RaaS solutions for both front and back of house

The hospitality industry is undergoing a radical transformation as automation promises to forever change the hotel labor landscape. With the rapid evolution of AI, robotics has undergone a seismic change. No longer an expensive novelty that delivered little value to hotel operators, robotics is becoming a must-have to remain in business and compete.

Combining the most advanced AI-driven robotics technology with its unique Robots-as-a-Service (“RaaS”) financial model, Nightfood Holdings (OTCQB: NGTF) is poised to lead the hospitality industry into the robotics age.

From mobile check-ins and digital room keys to online concierge services and smart room features, technology enables hotels to provide seamless experiences for both guests and staff. This not only boosts customer satisfaction but also improves operational efficiency by automating repetitive tasks and optimizing resource management. As we’ve seen in the past, falling behind on tech can be fatal.

This means the entire industry will be racing to adopt AI-driven robotics in the next one to three years. This is not optional.

As a leader hospitality tech, NGTF’s unique RaaS business model is a key differentiator investors should consider when placing their sector bets. RaaS allows hotel operators to quickly and easily incorporate mission-critical robotics without massive upfront capital expenditures.

Instead of having to purchase robotics upfront and then coordinate all elements of integration and maintenance, hotel operators can lease their robotics tech through NGTF. By doing this, a hotel can seamlessly integrate robotics into their operations with a simple line-item expense on their income statement. NGTF subsidiaries provide setup, installation, integration, training, and maintenance.

The benefits to NGTF are equally as powerful. Because RaaS significantly lowers barriers to entry, adoption rates go up and customer acquisition costs go down. The leases increase client satisfaction and create a sticky and predictable revenue stream with exceptionally high retention rates and customer lifetime value.

As the tech evolves at breakneck pace, hotels can easily upgrade to the latest version without being stuck with out of date “last year’s model.”

NGTF subsidiaries Skytech and Future Hospitality Ventures can automate everything from cleaning linens and trash removal to food preparation and deliveries.

The service robotics market is projected to reach $107.75 billion by 2030 (ibn.fm/k7Skz). How much investor value will be created in coming years in this sector?

This presents an opportunity for forward-thinking investors who can see the critical role robotics will play in hospitality (ibn.fm/QdUHm).

Nightfood’s recent acquisition of Skytech Automated Solutions (ibn.fm/Cd3Le) is a major industry development. Skytech’s leadership team has decades of experience in hotel management, business operations, and technology-driven solutions.

Skytech is best known for its AI-driven Laundry Helper robot. Laundry Helper picks up and transports laundry and trash, reducing the burden on housekeeping staff. Equipped with advanced sensors, AI navigation, and robotic arms, it can operate elevators and open doors on its own, making it the perfect housekeeping assistant for hotels.

Already successfully deployed in its first properties from InterContinental Hotels Group and Hilton Worldwide Holdings, the Skytech team has its sights set on rapid industry expansion for Laundry Helper, as well as its Concierge, Matradee, and Sweeper robots.

Synergies can be expected between these offerings and the food prep and delivery bots provided by NGTF subsidiary Future Hospitality, allowing hotel operators to procure all their RaaS needs through Nightfood Holdings.

The industry is at a tipping point. In a few years, hotels without integrated robotics will seem as antiquated as jingly keys, smoking rooms, and in-room VCRs.

NGTF is leading the way.

For more information, visit the company’s website at NightfoodHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF